Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Keytruda (pembrolizumab; Merck & Co) Drug Analysis 2016-2025 -

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: Keytruda" drug pipelines has been added to's offering.

Keytruda (pembrolizumab; Merck & Co) is a humanized monoclonal antibody designed to inhibit the programmed death-1 (PD-1) co-inhibitory receptor.

The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival and induces apoptosis of tumor-specific T cells. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses.

It has also been hypothesized that blocking the PD-1/PD-L1 interactions releases the cytotoxic function of tumor-specific T cells with fewer toxic effects than those seen with other immune checkpoint inhibitors.

Key Topics Covered:

Product Profiles

  1. Colorectal cancer (CRC)
  2. Head and neck cancer
  3. Hepatocellular carcinoma (HCC)
  4. Bladder cancer
  5. Renal cell cancer (RCC)
  6. Non-small cell lung cancer (NSCLC)
  7. NHL: Diffuse large B-cell lymphoma (DLBCL)
  8. Gastric cancer
  9. Breast cancer: triple-negative
  10. Melanoma
  11. Multiple myeloma

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.